Published in Leuk Res on February 03, 2009
The differential diagnosis of food intolerance. Dtsch Arztebl Int (2009) 2.82
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood (2012) 1.74
Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol (2011) 1.30
How I treat hypereosinophilic syndromes. Blood (2009) 1.07
Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract (2014) 1.04
A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood (2011) 1.01
Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML. Clin Med Insights Oncol (2011) 0.93
Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother (2013) 0.91
How I treat hypereosinophilic syndromes. Blood (2015) 0.91
Mastocytosis. Immunol Allergy Clin North Am (2013) 0.89
Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation. Leukemia (2012) 0.88
Pharmacological treatment options for mast cell activation disease. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.87
Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma (2010) 0.80
Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive. Case Rep Hematol (2012) 0.80
Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis. Leuk Lymphoma (2013) 0.79
Signal transduction and chemotaxis in mast cells. Eur J Pharmacol (2015) 0.77
Targeted Treatment Options in Mastocytosis. Front Med (Lausanne) (2017) 0.76
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J Cancer Res Clin Oncol (2015) 0.76
Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case. Case Rep Oncol Med (2016) 0.75
Mastocytosis 2016: Updated WHO Classification and Novel Emerging Treatment Concepts. Blood (2016) 0.75
Systemic Mastocytosis with Associated Clonal Hematological Non-Mast Cell Lineage Disorder (MDS-RCMD): A Difficult Disease to Diagnose and Treat. Indian J Hematol Blood Transfus (2015) 0.75
Systemic Mastocytosis Causing Refractory Pruritus in a Liver Disease Patient. ACG Case Rep J (2016) 0.75
Mastocytosis and systemic sclerosis: a clinical association. Clin Mol Allergy (2016) 0.75
Hypotension, Syncope, and Fever in Systemic Mastocytosis without Skin Infiltration and Rapid Response to Corticosteroid and Cyclosporin: A Case Report. Case Rep Med (2010) 0.75
A 26-Year-Old Female with Systemic Mastocytosis with Associated Myeloid Neoplasm with Eosinophilia and Abnormalities of PDGFRB, t(4;5)(q21;q33). Case Rep Hematol (2016) 0.75
Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget (2016) 0.75
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest (1993) 3.57
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther (2002) 2.68
Mastocytosis: state of the art. Pathobiology (2007) 1.64
Imatinib for systemic mast-cell disease. Lancet (2003) 1.62
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood (2003) 1.54
Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer (2006) 1.18
Novel approaches in the treatment of systemic mastocytosis. Cancer (2006) 1.03
Imatinib mesylate in the treatment of hematologic malignancies. Expert Opin Biol Ther (2007) 0.96
Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr Cancer Drug Targets (2007) 0.92
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med (2010) 10.64
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med (2012) 9.69
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood (2013) 8.00
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol (2008) 4.53
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res (2007) 4.42
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood (2006) 4.40
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood (2003) 4.07
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol (2011) 4.06
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res (2005) 4.00
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med (2011) 3.74
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood (2011) 3.71
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood (2002) 3.60
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 3.48
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer (2007) 3.28
Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med (2015) 3.25
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood (2005) 3.24
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2003) 3.18
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood (2002) 3.03
Functional proteomic profiling of AML predicts response and survival. Blood (2008) 2.90
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol (2012) 2.90
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol (2011) 2.89
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood (2009) 2.87
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 2.77
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer (2006) 2.77
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood (2003) 2.75
Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol (2007) 2.75
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res (2010) 2.69
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res (2006) 2.69
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 2.58
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol (2008) 2.54
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood (2012) 2.46
Targeting DNA methylation. Clin Cancer Res (2009) 2.45
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol (2003) 2.41
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov (2011) 2.38
Impact of cancer research bureaucracy on innovation, costs, and patient care. J Clin Oncol (2014) 2.34
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood (2012) 2.32
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer (2004) 2.31
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res (2006) 2.23
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood (2005) 2.21
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res (2009) 2.19
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood (2013) 2.18
Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer (2010) 2.17
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood (2009) 2.15
Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies. Oncology (Williston Park) (2012) 2.10
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer (2008) 2.07
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood (2003) 2.06
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell (2012) 2.04
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood (2013) 2.03
Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res (2012) 2.02
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol (2010) 2.02
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol (2008) 1.99
Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood (2006) 1.97
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med (2003) 1.95
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer (2007) 1.95
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol (2005) 1.93
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer (2003) 1.90
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol (2009) 1.88
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood (2003) 1.87
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood (2002) 1.87
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol (2007) 1.85
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood (2013) 1.83
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol (2009) 1.83
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood (2009) 1.82